Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
24 June 2023 - 2:05AM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare
company, today praised the Executive Order issued by President
Biden that addresses barriers in access to high quality
contraceptive care and family planning services. To ensure that
women have access to the reproductive healthcare that is right for
them, the President directed the tri-agencies, Department of Labor
(DOL), Health and Human Services (HHS) and Treasury, as well as
other agencies, to consider actions to address issues that have
been highlighted over the last several years regarding barriers in
access in contraceptive care.
Agile Therapeutics thanks the administration for
addressing the concerns of patients and providers and directing the
tri-agencies to consider releasing new guidance to ensure that
private health insurance under the Affordable Care Act covers all
Food and Drug Administration-approved, -granted, or -cleared
contraceptives without cost sharing and to streamline the process
for obtaining care women need and want. Agile Therapeutics supports
the broad approach the administration is taking by directing the
agencies to consider numerous other actions to improve access to
contraception and family planning services across multiple
dimensions.
"Birth control is a very personal decision, and
we agree that women should have no cost access without barriers to
the contraceptive product determined to be most appropriate for
them based on discussions with their healthcare provider. We know
there is additional work to be completed. We commend the Biden
Administration for recognizing the importance for all women to have
control over their family planning decisions without barriers. We
look forward to swift action by the agencies to address these
challenges.” said Kimberly Whelan, Agile Therapeutics Vice
President, Policy, Advocacy and Market Access.
Agile Therapeutics Chairperson and CEO Al
Altomari added, “we appreciate the hard work of the administration
and all those individuals and advocates that have been proactively
addressing these challenging situations for women and their
providers. We look forward to continuing to work with the
administration, providers, patients, insurers and health plans to
ensure that barriers to reproductive healthcare are
eliminated.”FACT SHEET: President Biden Issues Executive Order on
Strengthening Access to Contraception | The White House
About Agile Therapeutics,
Inc.
Agile Therapeutics is a women's healthcare
company dedicated to fulfilling the unmet health needs of today’s
women. Our product and product candidates are designed to provide
women with contraceptive options that offer freedom from taking a
daily pill, without committing to a longer-acting method. Our
initial product, Twirla®, (levonorgestrel and ethinyl estradiol)
transdermal system, is a non-daily prescription contraceptive.
Twirla is based on our proprietary transdermal patch technology,
called Skinfusion®, which is designed to allow drug delivery
through the skin. For more information, please visit the company
website at www.agiletherapeutics.com. The Company
may occasionally disseminate material, nonpublic information on the
Company’s website.
Forward-Looking Statements
Certain information contained in this press
release includes “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. We may in
some cases use terms such as “predicts,” “believes,” “potential,”
“continue,” “anticipates,” “estimates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “likely,” “will,” “should” or
other words that convey uncertainty of the future events or
outcomes to identify these forward-looking statements. Our
forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties, including
statements regarding third party coverage of contraceptives and
women’s affordable access to the contraceptives of their choice.
Any or all of the forward-looking statements may turn out to be
wrong or be affected by inaccurate assumptions we might make or by
known or unknown risks and uncertainties. These forward-looking
statements are subject to risks and uncertainties including risks
related to regulatory and legislative developments in the United
States and foreign countries, legal and regulatory compliance of
third parties outside our control, including the action of the
tri-agencies, and the other risks set forth in our filings with the
U.S. Securities and Exchange Commission, including our Annual
Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all
these reasons, actual results and developments could be materially
different from those expressed in or implied by our forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of
this press release. We undertake no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.
Contact:
Matt RileyHead of Investor
Relationsmriley@agiletherapeutics.com
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2024 to May 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From May 2023 to May 2024